In in vitro experiments using peripheral blood from patients with systemic sclerosis, ibrutinib reduced the production of pro-fibrotic cytokines IL-6 and tumor necrosis factor-α, while preserving the inhibitory role of IL-10, which helps suppress the overactivation of fibrotic functions in B cells (35). Here, IL10 is linked to systemic sclerosis.